RxDoctor Payments Data

Christopher Pivonka, PA

Physician Assistant · Knoxville, TNNPI 1881970044

Payments from drug & device makers

$6,647in general payments, 2019–2025

Across 398 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$857
  • Novo Nordisk$742
  • GSK$563
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$317
  • Axsome Therapeutics, Inc.$256
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$6,647100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,647 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$32,275
Medicare patients
56
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide202$278,514
FarxigaDapagliflozin Propanediol183$189,011
Breztri AerosphereBudesonide/Glycopyr/Formoterol117$141,052
VraylarCariprazine Hcl72$113,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$79,795
JanuviaSitagliptin Phosphate66$55,808
LinzessLinaclotide34$46,647
EliquisApixaban30$43,628
MounjaroTirzepatide24$33,370
JardianceEmpagliflozin11$20,812
Bydureon BciseExenatide Microspheres11$15,474
Repatha SureclickEvolocumab25$13,883
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$13,267
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$9,911
SymbicortBudesonide/Formoterol Fumarate18$9,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$857$339,208318 claims
Novo NordiskOzempic$742$278,514202 claims
AbbVieVraylar, Linzess, Viibryd$1,524$164,714117 claims
GSKTrelegy Ellipta, Anoro Ellipta$563$93,06176 claims
MerckJanuvia$51$55,80866 claims
PfizerEliquis$126$43,62830 claims
Lilly USA, LLCMounjaro$41$33,37024 claims
Boehringer IngelheimJardiance$198$20,81211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →